Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia
Purpose of Review
The present investigation is a comprehensive review regarding the use of Suvorexant for insomnia treatment. It covers the background, pathophysiology, and significance of addressing insomnia, the pharmaceutical details of Suvorexant, and its safety, efficacy, and implications in treating insomnia. We further discuss Suvorexant’s role in targeting insomnia with other comorbidities.
Recent Findings
Insomnia refers to poor quality and/or quantity of sleep. While there are many existing treatments such as benzodiazepines, melatonin agonists, TCAs, and atypical antipsychotics used to target various receptors involved in normal induction and maintenance of sleep, Suvorexant is an antagonist that specifically targets orexin receptors. Recent clinical studies suggest that Suvorexant is both clinically safe and effective. Quantity and quality of sleep are measured in various ways, yet the consensus points towards Suvorexant’s effectiveness in improving sleep time, onset, latency, and quality compared to placebo. In addition to helping improve isolated insomnia, Suvorexant helps improve sleep in patients that have other comorbidities such as obstructive sleep apnea, Alzheimer’s disease, dementia, acute stroke, and delirium. While Suvorexant is safe, there are still adverse effects associated with the drug that needs to be considered. The most common adverse effects include dizziness, somnolence, headaches, and cognitive impairment.
Summary
Insomnia is a major public health concern that affects many people worldwide and has been linked to many adverse health outcomes. While there are existing treatments that target different receptors and pathways of normal sleep induction and maintenance, Suvorexant is a novel drug that targets dual orexin receptors. Its safety and efficacy, mechanism of action, pharmacokinetic parameters, and relative lack of rebound and withdrawal effects render suvorexant a reliable choice for the treatment of insomnia.
1. Sutton EL. Insomnia. Medical Clinics of North America. 2014;98(3):565-581. doi:10.1016/j.mcna.2014.01.008
2. Roth T. Insomnia: Definition, prevalence, etiology, and consequences. Journal of Clinical Sleep Medicine. 2007;3(5 suppl). doi:10.5664/jcsm.26929
3. Mai E, Buysse DJ. Insomnia: Prevalence, Impact, Pathogenesis, Differential Diagnosis, and Evaluation. Sleep Medicine Clinics. 2008;3(2):167-174. doi:10.1016/j.jsmc.2008.02.001
4. Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. American Journal of Managed Care. Published online 2006.
5. Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews. 2002;6(2):97-111. doi:10.1053/smrv.2002.0186
6. Morin CM, Bélanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med. 2009;169(5):447. doi:10.1001/archinternmed.2008.610
7. Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry. 2019;18(3):337-352. doi:10.1002/wps.20674
8. Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews. 2002;6(2):97-111. doi:10.1053/smrv.2002.0186
9. Leger D, Guilleminault C, Dreyfus JP, Delahaye C, Paillard M. Prevalence of insomnia in a survey of 12778 adults in France. J Sleep Res. 2000;9(1):35-42. doi:10.1046/j.1365-2869.2000.00178.x
10. Bixler EO, Kales A, Soldatos CR, Kales JD, Healey S. Prevalence of sleep disorders in the Los Angeles metropolitan area. American Journal of Psychiatry. 1979;136(10):1257-1262. doi:10.1176/ajp.136.10.1257
11. Grandner MA. Sleep, Health, and Society. Sleep Medicine Clinics. 2017;12(1):1-22. doi:10.1016/j.jsmc.2016.10.012
12. Suls J, Green PA, Davidson KW. A biobehavioral framework to address the emerging challenge of multimorbidity. Psychosomatic Medicine. 2016;78(3):281-289. doi:10.1097/psy.0000000000000294
13. Shi T, Min M, Sun C, Zhang Y, Liang M, Sun Y. Does insomnia predict a high risk of cancer? A systematic review and meta-analysis of cohort studies. J Sleep Res. 2020;29(1). doi:10.1111/jsr.12876
14. Maggi S, Langlois JA, Minicuci N, et al. Sleep complaints in community-dwelling older persons: Prevalence, associated factors, and reported causes. Journal of the American Geriatrics Society. 1998;46(2):161-168. doi:10.1111/j.1532-5415.1998.tb02533.x
15. Ford DE, Kamerow DB. Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention? JAMA. 1989;262(11):1479. doi:10.1001/jama.1989.03430110069030
16. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: An epidemiologic study of three communities. Sleep. 1995;18(6):425-432. doi:10.1093/sleep/18.6.425
17. Henderson S, Jorm AF, Scott LR, MacKinnon AJ, Christensen H, Korten AE. Insomnia in the elderly: Its prevalence and correlates in the general population. Medical Journal of Australia. 1995;162(1):22-24. doi:10.5694/j.1326-5377.1995.tb138406.x
18. Tamura H, Nishida T, Tsuji A, Sakakibara H. Association between excessive use of mobile phone and insomnia and depression among Japanese adolescents. International Journal of Environmental Research and Public Health. 2017;14(7):701. doi:10.3390/ijerph14070701
19. Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest. 2015;147(4):1179-1192. doi:10.1378/chest.14-1617
20. Carley DW, Farabi SS. Physiology of sleep. Diabetes Spectrum. 2016;29(1):5-9. doi:10.2337/diaspect.29.1.5
21. Kaur H, Bollu PC. Insomnia, Chronic. StatPearls Publishing; 2018.
22. Scammell TE, Winrow CJ. Orexin receptors: Pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51(1):243-266. doi:10.1146/annurev-pharmtox-010510-100528
23. Asnis GM, Thomas M, Henderson MA. Pharmacotherapy treatment options for insomnia: A primer for clinicians. International Journal of Molecular Sciences. 2015;17(1):50. doi:10.3390/ijms17010050
24. Lie JD, Tu KN, Shen DD, Wong BM. Pharmacological Treatment of Insomnia.
25. Triazolam | C17H12Cl2N4 - PubChem. Accessed June 13, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Triazolam
26. McGechan A, Wellington K. Ramelteon. CNS Drugs. 2005;19(12):1057-1065. doi:10.2165/00023210-200519120-00007
27. Almasi A, Meza CE. Doxepin - StatPearls - NCBI Bookshelf. Accessed June 13, 2021. https://www.ncbi.nlm.nih.gov/books/NBK542306/?report=reader
28. HIGHLIGHTS OF PRESCRIBING INFORMATION.
29. U.S. Food and Drug Administration, Merck & Co. Inc. Belsomra® (Suvorexant); 2014.
30. Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nature and Science of Sleep. 2016;8:239-247. doi:10.2147/nss.s76910
31. Gauld AR. Suvorexant (Belsomra) for insomnia. American Family Physician. Published online 2016.
32. Citrome L. Suvorexant for insomnia: A systematic review of the efficacy and safety profile for this newly approved hypnotic - What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(12):1429-1441. doi:10.1111/ijcp.12568
33. U.S. Food and Drug Administration, Merck & Co. Inc. Belsomra® (Suvorexant); 2014.
34. Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. Journal of Clinical Sleep Medicine. 2018;14(8):1399-1408. doi:10.5664/jcsm.7282
35. Citrome L. Suvorexant for insomnia: A systematic review of the efficacy and safety profile for this newly approved hypnotic - What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(12):1429-1441. doi:10.1111/ijcp.12568
36. Gauld AR. Suvorexant (Belsomra) for insomnia. American Family Physician. Published online 2016.
37. Cada D, Levien T, Baker D. Suvorexant. Hospital Pharmacy. 2015;50(1):059-071. doi:10.1310/hpj5001-059
38. Uslaner JM, Renger JJ, Coleman PJ, Winrow CJ. A new class of hypnotic compounds for the treatment of insomnia: The dual orexin receptor antagonists. Orexin and Sleep. Published online 2015:323-338. doi:10.1007/978-3-319-23078-8_17
39. Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology. 2014;7(6):711-730. doi:10.1586/17512433.2014.966813
40. Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 receptor antagonists as sleep aids. Current Topics in Behavioral Neurosciences. Published online 2017:105-136. doi:10.1007/7854_2016_47
41. Snyder E, Ma J, Svetnik V, et al. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: Analysis of pooled phase 3 data. Sleep Medicine. 2016;19:93-100. doi:10.1016/j.sleep.2015.10.007
42. Gotter AL, Winrow CJ, Brunner J, et al. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci. 2013;14(1). doi:10.1186/1471-2202-14-90
43. Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology. 2014;7(6):711-730. doi:10.1586/17512433.2014.966813
44. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2014;13(5):461-471. doi:10.1016/s1474-4422(14)70053-5
45. Dubey AK, Handu SS, Mediratta PK. Suvorexant: The first orexin receptor antagonist to treat insomnia. Journal of Pharmacology and Pharmacotherapeutics. 2015;6(2):118-121. doi:10.4103/0976-500x.155496
46. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. Published online February 1, 2013. doi:10.5665/sleep.2386
47. Cada D, Levien T, Baker D. Suvorexant. Hospital Pharmacy. 2015;50(1):059-071. doi:10.1310/hpj5001-059
48. Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Therapeutic Advances in Drug Safety. 2015;6(5):189-195. doi:10.1177/2042098615595359
49. Dubey AK, Handu SS, Mediretta PK. Suvorexant: The first orexin receptor antagonist to treat insomnia. Journal of Pharmacology and Pharmacotherapeutics. 2015;6(2):118-121. doi:10.4103/0976-500x.155496
50. Sun H, Kennedy D, Lewis N, et al. THE SINGLE DOSE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILES OF SUVOREXANT (MK-4305), A DUAL OREXIN RECEPTOR ANTAGONIST, IN HEALTHY MALE SUBJECTS. Clinical Pharmacology & Therapeutics. Published online 2012.
51. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. Published online February 1, 2013. doi:10.5665/sleep.2386
52. Cui D, Cabalu T, Yee KL, et al. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. Xenobiotica. 2016;46(10):882-895. doi:10.3109/00498254.2015.1129565
53. Asai Y, Sano H, Miyazaki M, Iwakura M, Maeda Y, Hara M. Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey. Drugs R D. 2018;19(1):27-46. doi:10.1007/s40268-018-0256-6
54. Fan B, Kang J, He Y, Hao M, Du W, Ma S. Efficacy and Safety of Suvorexant for the Treatment of Primary Insomnia among Chinese: A 6-Month Randomized Double-Blind Controlled Study.
55. Svetnik V, Snyder ES, Tao P, et al. Insight into reduction of wakefulness by suvorexant in patients with insomnia: Analysis of wake bouts. Sleep. 2018;41(1). doi:10.1093/sleep/zsx178
56. Seol J, Fujii Y, Park I, et al. Distinct effects of orexin receptor antagonist and GABA A agonist on sleep and physical/cognitive functions after forced awakening. Proc Natl Acad Sci USA. 2019;116(48):24353-24358. doi:10.1073/pnas.1907354116
57. Herring WJ, Connor KM, Snyder E, et al. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. Sleep Medicine. 2019;56:219-223. doi:10.1016/j.sleep.2018.09.010
58. Kawabe K, Horiuchi F, Ochi M, Nishimoto K, Ueno SI, Oka Y. Suvorexant for the Treatment of Insomnia in Adolescents. Journal of Child and Adolescent Psychopharmacology. 2017;27(9):792-795. doi:10.1089/cap.2016.0206
59. Takeuchi Y, Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y. Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan. Current Medical Research and Opinion. 2020;36(3):465-471. doi:10.1080/03007995.2019.1700361
60. Herring WJ, Connor KM, Snyder E, et al. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Psychopharmacology. 2017;234(11):1703-1711. doi:10.1007/s00213-017-4573-1
61. Yee KL, McCrea J, Panebianco D, et al. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clin Drug Investig. 2018;38(7):631-638. doi:10.1007/s40261-018-0650-4
62. Wrishko RE, McCrea JB, Yee KL, et al. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clin Drug Investig. 2019;39(5):441-451. doi:10.1007/s40261-019-00764-x
63. Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y, Hara M. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey. Expert Opinion on Drug Safety. 2019;18(11):1109-1118. doi:10.1080/14740338.2019.1657091
64. Herring WJ, Connor KM, Snyder E, et al. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. American Journal of Geriatric Psychiatry. 2017;25(7):791-802. doi:10.1016/j.jagp.2017.03.004
65. Matsumura T, Terada J, Yoshimura C, et al. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Drug Design, Development and Therapy. 2019;13:809-816. doi:10.2147/dddt.s197237
66. Herring WJ, Ceesay P, Snyder E, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimer's & Dementia. 2020;16(3):541-551. doi:10.1002/alz.12035
67. Hamuro A, Honda M, Wakaura Y. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease. Aust NZJ Psychiatry. 2018;52(2):207-208. doi:10.1177/0004867417747402
68. Kawada K, Ohta T, Tanaka K, Miyamura M, Tanaka S. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients. Journal of Stroke and Cerebrovascular Diseases. 2019;28(1):142-148. doi:10.1016/j.jstrokecerebrovasdis.2018.09.024
69. Toi N, Inaba M, Kurajoh M, et al. Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus. Journal of Clinical & Translational Endocrinology. 2019;15:37-44. doi:10.1016/j.jcte.2018.12.006
70. Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull. 2019;36(4):432-448. doi:10.1007/s12264-019-00447-9
71. Sheridan C. Insomniacs get new mechanism sleep drug Belsomra. Nat Biotechnol. 2014;32(10):968-968. doi:10.1038/nbt1014-968
72. Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nature and Science of Sleep. 2016;8:239-247. doi:10.2147/nss.s76910